| |
|
| Source: Company documents |
|
| Name
: |
Michael Chen |
| Title
: |
Vice President for Global Business Development |
| Since: |
05/2006 |
|
|
|
|
| Name
: |
Robert G. Savage |
| Title
: |
Chairman of the Board |
| Since: |
12/2004 |
|
|
|
| Name
: |
Jack V. Talley |
| Title
: |
President, Chief Executive Officer, Director |
| Since: |
10/2001 |
|
|
|
| Name
: |
Robert W. Cook |
| Title
: |
Chief Financial Officer, Senior Vice President - Finance and Administration |
| Since: |
04/2004 |
|
|
|
| Name
: |
Dileep Bhagwat |
| Title
: |
Senior Vice President - Pharmaceutical Development |
| Since: |
02/2004 |
|
|
|
| Name
: |
Ben Tseng |
| Title
: |
Chief Scientific Officer |
| Since: |
01/2006 |
|
|
|
| Name
: |
Stephane Allard |
| Title
: |
Chief Medical Officer |
| Since: |
03/26/2007 |
|
|
|
| Name
: |
Oliver Wiedemann |
| Title
: |
Managing Director - Medical Affairs of EpiCept GmbH |
| Since: |
07/1999 |
|
|
|
|
|
|
|
| |
|
| Earnings
Release Dates : 29th February 2008 , 5th November 2007 , 13th August 2007 |
|
 Audio |
|
|
| |
|
| |
|
| |
|
|
| |
Epicept Corp.
The Company has six product candidates in clinical development; three in late-stage clinical development that are ready to enter, or have entered, pivotal Phase IIb or Phase III clinical trials, and three that have completed initial Phase II clinical trials.
The Company’s lead late-stage product candidate is a prescription topical analgesic cream containing a patented formulation, the contents of which include two FDA-approved drugs, amitriptyline and ketamine.
|
| More... |
|
|
|
